Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

This study tests a three-drug combination — belantamab mafodotin (an antibody-drug conjugate that targets myeloma cells), carfilzomib (a proteasome inhibitor), and dexamethasone — for multiple myeloma patients whose cancer has come back and stopped responding to lenalidomide. **You may be eligible if...** - You have relapsed multiple myeloma and have received 1 to 3 prior lines of treatment - Your cancer is no longer responding to lenalidomide (i.e., it progressed while on it or within 60 days of stopping) - You are willing and able to follow the study schedule **You may NOT be eligible if...** - You have had more than 3 prior lines of therapy - You are refractory to carfilzomib (unless you haven't received it before) - You have severe active infections, uncontrolled disease, or other conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.